David Knopman (Mayo Clinic via YouTube)

A sec­ond ad­comm mem­ber aban­dons his post in af­ter­math of con­tro­ver­sial ad­u­canum­ab de­ci­sion

As the fall­out from the FDA’s ap­proval of Alzheimer’s med ad­u­canum­ab grows, a sec­ond mem­ber of the ad­comm over­see­ing that drug’s re­view has walked away …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.